Skip to main navigation
Skip to content
InMed-logo-01

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Subscribe
NASDAQ_Logo

Andrew Hull BA

Andrew Hull

Andrew Hull BA

Director

Mr. Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He most recently served as Vice President of Global Alliances for Takeda Pharmaceuticals where he was responsible

for maximizing the success of Takeda’s growing number (40+) of commercial and R&D partnerships with many of the industry’s leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda’s United States portfolio of over $3 billion, including diabetes, neuroscience, gastrointestinal and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Laboratories.

Mr. Hull received a bachelor’s degree in biology from Kenyon College in 1985. He also recently served as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and recently was a member of the Kenyon College Board of Trustees. Mr. Hull serves as a Director of Zucara Therapeutics, Inc.

  • Member of the Audit Committee
  • Chair of the Compensation Committee
  • Member of the Nominating and Governance Committee

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Rare Cannabinoid Manufacturing

Manufacturing

  • Cannabinoid Manufacturing Capabilities
  • IntegraSyn™ - Cannabinoid Manufacturing
  • Baymedica Cannabinoid Biosynthesis

Pharmaceutical Programs

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Cannabinoids in Development

IR Nav

Investor

  • News Releases
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

Products

  • Cannabichromene (CBC)
  • Cannabicitran (CBT)
  • Cannabidivarin (CBDV)

About

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • FAQ
  • Careers
  • Contact

Learn

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabis Treatments for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

Legal Nav

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer

Social icons

  • Find Us On:
  • >
  • >
  • >